The IPO Buzz: Hemab Therapeutics (COAG) Prices Upsized IPO at $18 – Top of Range
Twice is nice. Hemab Therapeutics (COAG) upsized its IPO again at pricing last night – increasing its size to 16.75 million shares – up from 15 million shares earlier in the day – and priced its IPO at $18.00 – the top of its range – to raise $301.5 million on Thursday night, April 30, 2026. The Hemab IPO's original terms had called for 11.76 million shares at a price range of $16.00 to..
Read more May 1, 2026IPO Calendar
| Company | Symbol proposed | Shares (Millions) | Est. $ Volume | Expected to Trade | SCOOP Rating | Rating Change |
|---|---|---|---|---|---|---|
| ARC Group Acquisition I | ARBCU | 10.5 | $ 105.0 mil | 4/30/2026 Priced | S/O | S/O |
| Avalyn Pharma | AVLN | 16.7 | $ 300.1 mil | 4/30/2026 Priced | S/O | S/O |
| Forefront Tech Holdings Acquisition | FTHAU | 10.0 | $ 100.0 mil | 4/30/2026 Priced | S/O | S/O |
Last 100 IPOs - April 30, 2026
| Number of IPOs priced : | 100 |
| Number Up: | 45 |
| Number Down: | 51 |
| Number Unchanged: | 4 |
| Percentage Change From Issue Price: | -13.89% |
| Percentage Change for The Nasdaq Composite | 35.22% |
2026 IPO Scorecard - April 30, 2026
| Number of IPOs priced (Excluding 78 units) : | 53 |
| Number Up: | 25 |
| Number Down: | 27 |
| Number Unchanged: | 1 |
| Total Return From Issue Price: | -7.88% |
| The Nasdaq Composite Index YTD % Change | 35.22% |